Re: Press ReleaseSource: BioMS Medical Corp.

[Guest guest]

I live in Edmonton and emailed these people about possibly getting in

on their trials, but must have been too late or they had enough

patients. But they did email me back to thank me for contacting them.

This apparently is a synthetic peptide?? Seems very promising. We

can only hope.

Kathy

On 26-Oct-04, at 9:32 AM, Cabbie54@... wrote:

> Press ReleaseSource: BioMS Medical Corp.

>

>

> BioMS Medical Provides Multiple Sclerosis Trial Update

> Tuesday October 26, 7:00 am ET

>

> - Dr. Mark Freedman announced as Lead Investigator -

>

> TSX: MS

>

> EDMONTON, Oct. 26 /CNW/ - BioMS Medical Corp (TSX: MS - News), a

> leading developer in the treatment of multiple sclerosis (MS), is

> pleased to

> announce Dr. Mark Freedman, Professor of Neurology at the University of

> Ottawa and Director of the Multiple Sclerosis Research Clinic at the

> Ottawa

> Hospital, as lead investigator for the Company's pivotal Phase II/III

> clinical trial

> of its lead drug MBP8298.

>

> " I am pleased to play a key role in one of the only later-stage

> clinical trials

> assessing new therapies for secondary progressive multiple sclerosis,

> a form

> of the disease for which there are few approved therapies, " said Dr.

> Freedman. " This trial will assess the impact of this drug on disease

> progression and further our understanding of its underlying

> immunology. "

>

> Dr. Freedman, B.Sc. M.Sc. M.D. CSPQ FAAN FRCPC, earned his medical

> degree at the University of Toronto, and performed post graduate

> training at

> the University of Toronto, Queen Square (London, UK), McGill and the

> Weizmann Institute of Science (Israel). He has published more than 100

> papers, book chapters and reviews on MS. Dr. Freedman is also a Fellow

> of

> the American Academy of Neurology, serves on the medical advisory

> committee for the MS Society of Canada and is a member of the

> clinical trial

> group for the National MS Society (USA). As Director of the Multiple

> Sclerosis

> Research Clinic at the Ottawa Hospital, he operates a large and

> successful

> MS research unit with approximately 3000 patients.

>

> " The interest in our trial amongst other leading MS clinicians in

> Canada has

> been very positive, and enrollment of patients is targeted to commence

> soon

> at a number of sites, " said Giese, President of BioMS Medical.

> " Dr.

> Freedman's leadership role in our trial is supported by his past 20

> years of

> experience in the clinical development of the current major MS

> therapies. "

>

> The trial, approved by Health Canada on June 8, 2004, will enroll up

> to 553

> patients and is designed to evaluate the efficacy and safety of

> MBP8298 in

> patients with secondary progressive MS. The Company also intends to

> seek

> regulatory approval for the trial outside of Canada to enroll patients

> on an

> international basis.

>

> About BioMS Medical Corp.

>

> -------------------------

>

> BioMS Medical Corp. is a biotechnology company dedicated to the

> development and commercialization of innovative therapies. BioMS

> Medical's

> patented MBP8298 technology for the treatment of multiple sclerosis has

> undergone Phase I and II human clinical trials and has recently been

> approved to enter into a pivotal Phase II/III clinical trial. In

> addition, the

> Company has a platform technology, HYC750, involving a method for the

> potential mobilization of stem cells and neutrophils for the treatment

> of cancer

> therapy related side-effects, as well as an interest in BioCyDex, a

> private

> company developing platform drug and gene delivery and imaging

> technology.

>

> BioMS trades on the Toronto St

>

>

>

>

>

>

> A support group for people with ms & their friends & relations. We

> try & keep informed of developments in ms research & stay abreast of

> legislative issues that may effect us.

>